These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 32606576)

  • 21. Three different phenotypes of mild nonproliferative diabetic retinopathy with different risks for development of clinically significant macular edema.
    Nunes S; Ribeiro L; Lobo C; Cunha-Vaz J
    Invest Ophthalmol Vis Sci; 2013 Jul; 54(7):4595-604. PubMed ID: 23745006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized Trial of Treat and Extend Ranibizumab with and without Navigated Laser for Diabetic Macular Edema: TREX-DME 1 Year Outcomes.
    Payne JF; Wykoff CC; Clark WL; Bruce BB; Boyer DS; Brown DM;
    Ophthalmology; 2017 Jan; 124(1):74-81. PubMed ID: 27836430
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Ranibizumab and aflibercept for diabetic macular edema-retrospective study with real-life data after 12 months].
    Holbach B; Zeman F; Helbig H; Gamulescu MA
    Ophthalmologe; 2020 Jul; 117(7):687-692. PubMed ID: 31705192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Retinal function in eyes with proliferative diabetic retinopathy treated with intravitreal ranibizumab and multispot laser panretinal photocoagulation.
    Messias K; Barroso RM; Jorge R; Messias A
    Doc Ophthalmol; 2018 Oct; 137(2):121-129. PubMed ID: 30209775
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment: 18-Month, Multicenter, Phase IIIB RELIGHT Study.
    Pearce I; Banerjee S; Burton BJ; Chakravarthy U; Downey L; Gale RP; Gibson J; Pagliarini S; Patel J; Sivaprasad S; Andrews C; Brittain C; Warburton J;
    Ophthalmology; 2015 Sep; 122(9):1811-9. PubMed ID: 26150052
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relation between macular morphology and treatment frequency during twelve months with ranibizumab for diabetic macular edema.
    Mori Y; Murakami T; Suzuma K; Ishihara K; Yoshitake S; Fujimoto M; Dodo Y; Yoshitake T; Miwa Y; Tsujikawa A
    PLoS One; 2017; 12(4):e0175809. PubMed ID: 28407012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes after a 1-Year Treatment with Ranibizumab for Diabetic Macular Edema in a Clinical Setting.
    Hrarat L; Fajnkuchen F; Boubaya M; Lévy V; Sarda V; Grenet T; Nghiem-Buffet S; Chaine G; Giocanti-Auregan A
    Ophthalmologica; 2016; 236(4):207-214. PubMed ID: 27898414
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural and functional assessment after intravitreal injection of ranibizumab in diabetic macular edema.
    Fu Y; Wang P; Meng X; Du Z; Wang D
    Doc Ophthalmol; 2017 Dec; 135(3):165-173. PubMed ID: 28756595
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The RELATION study: efficacy and safety of ranibizumab combined with laser photocoagulation treatment versus laser monotherapy in NPDR and PDR patients with diabetic macular oedema.
    Lang GE; Liakopoulos S; Vögeler J; Weiß C; Spital G; Gamulescu MA; Lohmann C; Wiedemann P
    Acta Ophthalmol; 2018 May; 96(3):e377-e385. PubMed ID: 29090846
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-life clinical data for dexamethasone and ranibizumab in the treatment of branch or central retinal vein occlusion over a period of six months.
    Winterhalter S; Eckert A; Vom Brocke GA; Schneider A; Pohlmann D; Pilger D; Joussen AM; Rehak M; Grittner U
    Graefes Arch Clin Exp Ophthalmol; 2018 Feb; 256(2):267-279. PubMed ID: 29185099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of 12-month therapeutic effect of conbercept and ranibizumab for diabetic macular edema: a real-life clinical practice study.
    Xu Y; Rong A; Xu W; Niu Y; Wang Z
    BMC Ophthalmol; 2017 Aug; 17(1):158. PubMed ID: 28841827
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of Ranibizumab in Eyes with Diabetic Macular Edema and Macular Nonperfusion in RIDE and RISE.
    Reddy RK; Pieramici DJ; Gune S; Ghanekar A; Lu N; Quezada-Ruiz C; Baumal CR
    Ophthalmology; 2018 Oct; 125(10):1568-1574. PubMed ID: 29752001
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sustained Benefits from Ranibizumab for Central Retinal Vein Occlusion with Macular Edema: 24-Month Results of the CRYSTAL Study.
    Larsen M; Waldstein SM; Priglinger S; Hykin P; Barnes E; Gekkieva M; Das Gupta A; Wenzel A; Monés J;
    Ophthalmol Retina; 2018 Feb; 2(2):134-142. PubMed ID: 31047340
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optical coherence tomography findings as a predictor of clinical course in patients with branch retinal vein occlusion treated with ranibizumab.
    Shiono A; Kogo J; Sasaki H; Yomoda R; Jujo T; Tokuda N; Kitaoka Y; Takagi H
    PLoS One; 2018; 13(6):e0199552. PubMed ID: 29924853
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of Retinal Disease Progression in a 1-Year Longitudinal Study of Eyes With Mild Nonproliferative Retinopathy in Diabetes Type 2.
    Ribeiro L; Bandello F; Tejerina AN; Vujosevic S; Varano M; Egan C; Sivaprasad S; Menon G; Massin P; Verbraak FD; Lund-Andersen H; Martinez JP; Jürgens I; Smets E; Coriat C; Wiedemann P; Ágoas V; Querques G; Holz FG; Nunes S; Neves C; Cunha-Vaz J;
    Invest Ophthalmol Vis Sci; 2015 Aug; 56(9):5698-705. PubMed ID: 26322834
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of 2-Year Outcomes between Intravitreal Ranibizumab and Intravitreal Aflibercept for Diabetic Macular Edema with "Treat-and-Extend" Regimen-Its Usefulness and Problems.
    Chujo S; Sugimoto M; Sasaki T; Matsui Y; Kato K; Ichio A; Miyata R; Matsubara H; Kondo M
    J Clin Med; 2020 Sep; 9(9):. PubMed ID: 32887464
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term full-field and multifocal electroretinographic changes after treatment with ranibizumab in patients with diabetic macular edema.
    Yigit K; Inan ÜÜ; Inan S; Dogan M; Yavas GF; Cetinkaya E
    Int Ophthalmol; 2021 Apr; 41(4):1487-1501. PubMed ID: 33486648
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decrease in the number of microaneurysms in diabetic macular edema after anti-vascular endothelial growth factor therapy: implications for indocyanine green angiography-guided detection of refractory microaneurysms.
    Mori K; Yoshida S; Kobayashi Y; Ishikawa K; Nakao S; Hisatomi T; Haruta M; Isihibashi T; Sonoda KH
    Graefes Arch Clin Exp Ophthalmol; 2020 Apr; 258(4):735-741. PubMed ID: 31960130
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparing the Efficacy of Bevacizumab and Ranibizumab in Patients with Diabetic Macular Edema (BRDME): The BRDME Study, a Randomized Trial.
    Vader MJC; Schauwvlieghe AME; Verbraak FD; Dijkman G; Hooymans JMM; Los LI; Zwinderman AH; Peto T; Hoyng CB; van Leeuwen R; Vingerling JR; Moll AC; van Lith-Verhoeven JJC; Dijkgraaf MGW; Schlingemann RO;
    Ophthalmol Retina; 2020 Aug; 4(8):777-788. PubMed ID: 32362552
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES): six-month results of a prospective randomized clinical trial.
    Pielen A; Mirshahi A; Feltgen N; Lorenz K; Korb C; Junker B; Schaefer C; Zwiener I; Hattenbach LO;
    Acta Ophthalmol; 2015 Feb; 93(1):e29-37. PubMed ID: 25042729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.